Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The POWER Trial: A Randomised, Two-armed Open Label Phase 3 Clinical Trial on Personalised Dose Optimisation With Adjuvant Tamoxifen Therapy After Breast Cancer to Investigate the Impact on Discontinuation and Efficacy Compared to Standard of Care

NCT07502820 is registered in ClinicalTrials.gov with Karolinska Institutet as lead sponsor.

NCT NCT07502820
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07502820 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The POWER Trial: A Randomised, Two-armed Open Label Phase 3 Clinical Trial on Personalised Dose Optimisation With Adjuvant Tamoxifen Therapy After Breast Cancer to Investigate the Impact on Discontinuation and Efficacy Compared to Standard of Care
Lead sponsor
Karolinska Institutet
Phase
Phase 3
Overall status
Recruiting
Start date
April 14, 2026
Completion date
August 31, 2036
Enrollment
1,100 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

adjuvant drug therapy, breast cancer